Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular Carcinoma

NCT02509169 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Hepatocellular Carcinoma (HCC)

Interventions

DRUG: TAE plus P53 gene
OTHER: TAE

Sponsor

Shenzhen SiBiono GeneTech Co.,Ltd